- Home
- IPA vs BOLT Comparison
IPA vs BOLT Comparison
Compare IPA & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- BOLT
- Stock Information
- Founded
- IPA 1983
- BOLT 2015
- Country
- IPA Canada
- BOLT United States
- Employees
- IPA N/A
- BOLT N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- BOLT Health Care
- Exchange
- IPA Nasdaq
- BOLT Nasdaq
- Market Cap
- IPA 19.3M
- BOLT 22.6M
- IPO Year
- IPA 2017
- BOLT 2021
- Fundamental
- Price
- IPA $0.39
- BOLT $0.49
- Analyst Decision
- IPA Strong Buy
- BOLT Hold
- Analyst Count
- IPA 2
- BOLT 5
- Target Price
- IPA $5.00
- BOLT $1.25
- AVG Volume (30 Days)
- IPA 1.3M
- BOLT 114.3K
- Earning Date
- IPA 03-13-2025
- BOLT 03-20-2025
- Dividend Yield
- IPA N/A
- BOLT N/A
- EPS Growth
- IPA N/A
- BOLT N/A
- EPS
- IPA N/A
- BOLT N/A
- Revenue
- IPA $17,272,336.00
- BOLT $9,779,000.00
- Revenue This Year
- IPA $1.88
- BOLT $9.87
- Revenue Next Year
- IPA $9.90
- BOLT N/A
- P/E Ratio
- IPA N/A
- BOLT N/A
- Revenue Growth
- IPA 6.36
- BOLT 35.86
- 52 Week Low
- IPA $0.33
- BOLT $0.46
- 52 Week High
- IPA $2.43
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- IPA 36.66
- BOLT 45.52
- Support Level
- IPA $0.43
- BOLT $0.48
- Resistance Level
- IPA $0.53
- BOLT $0.52
- Average True Range (ATR)
- IPA 0.04
- BOLT 0.03
- MACD
- IPA -0.01
- BOLT 0.00
- Stochastic Oscillator
- IPA 8.42
- BOLT 40.32
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.